Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Tizanidine
Drug ID BADD_D02230
Description Tizanidine is a fast-acting drug used for the management of muscle spasm, which may result from the effects of multiple sclerosis, stroke, an acquired brain injury, or a spinal cord injury [T574]. It may also be caused by musculoskeletal injury [A177583]. Regardless of the cause, muscle spasticity can be an extremely painful and debilitating condition. Initially approved by the FDA in 1996, tizanidine is an Alpha-2 adrenergic receptor agonist reducing spasticity by the presynaptic inhibition of excitatory neurotransmitters that cause firing of neurons promoting muscle spasm [FDA label].
Indications and Usage Tizanidine is indicated for the relief of muscle spasticity, which can interfere with daily activities. The general recommendation is to reserve tizanidine use for periods of time when there is a particular need for relief, as it has a short duration of action [FDA label, F4471].
Marketing Status approved; investigational
ATC Code M03BX02
DrugBank ID DB00697
KEGG ID D08611
MeSH ID C023754
PubChem ID 5487
TTD Drug ID D01MDT
NDC Product Code 72789-325; 35356-662; 50090-0840; 51655-740; 53002-1418; 57664-502; 60760-694; 70771-1335; 72578-096; 61919-221; 63187-009; 63187-910; 63629-8533; 68084-645; 29300-168; 29300-169; 42291-809; 55111-180; 60760-263; 63629-2371; 71610-228; 60760-505; 63187-493; 63187-673; 68084-775; 70518-3658; 71610-451; 0615-8468; 72578-097; 0904-6418; 43063-868; 60505-0251; 60760-782; 67877-614; 68071-5268; 70518-2210; 70771-1336; 71205-311; 71335-1016; 71335-1799; 0615-8360; 76420-228; 55111-179; 60505-0252; 60760-719; 63629-3209; 67877-613; 68788-7782; 70518-3181; 71610-162; 71610-455; 42291-808; 50090-0841; 63187-145; 63629-1673; 67296-1599; 70518-0133; 70518-1439; 70518-3112; 71610-167; 0615-8274; 0615-8469; 72789-326; 16714-172; 50090-0811; 50090-5767; 51655-603; 53002-1437; 68071-3440; 70518-0573; 72789-327; 76420-229; 43063-455; 55154-7287; 57664-503; 63629-2370; 68788-7781; 68788-7991; 16714-171; 71335-0914; 43353-167; 50268-759; 50268-760
UNII 6AI06C00GW
Synonyms tizanidine | 5-chloro-4-(2-imidazolin-2-yl-amino)-2,1,3-benzothiadiazole | Zanaflex | tizanidine hydrochloride | tizanidine monohydrochloride | DS 103-282 | Sirdalud
Chemical Information
Molecular Formula C9H8ClN5S
CAS Registry Number 51322-75-9
SMILES C1CN=C(N1)NC2=C(C=CC3=NSN=C32)Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal discomfort07.01.06.0010.000141%Not Available
Abdominal pain07.01.05.0020.000141%
Abnormal dreams19.02.03.001; 17.15.02.001--Not Available
Abscess11.01.08.001--Not Available
Acne23.02.01.001--Not Available
Acute hepatic failure09.01.03.0010.000052%Not Available
Adrenal insufficiency14.11.01.004; 05.01.02.001--
Aggression19.05.01.0010.000052%Not Available
Agitation19.06.02.001; 17.02.05.0120.000178%
Agranulocytosis01.02.03.001--Not Available
Alanine aminotransferase increased13.03.04.005--
Albuminuria20.02.01.001--Not Available
Alopecia23.02.02.001--
Altered state of consciousness19.07.01.003; 17.02.04.0010.000105%Not Available
Amblyopia06.02.01.001--Not Available
Anaemia01.03.02.001--
Anaphylactic reaction24.06.03.006; 10.01.07.0010.000052%
Anaphylactic shock24.06.02.004; 10.01.07.002--Not Available
Angina pectoris24.04.04.002; 02.02.02.002--
Anxiety19.06.02.0020.000141%
Arrhythmia02.03.02.001--Not Available
Arthralgia15.01.02.001--
Arthritis15.01.01.001--
Asthenia08.01.01.0010.000413%Not Available
Asthma10.01.03.010; 22.03.01.002--Not Available
Atrioventricular block complete02.03.01.0030.000183%
Autonomic nervous system imbalance24.06.01.005; 17.05.01.011; 08.01.01.010--Not Available
Back pain15.03.04.005--
Bladder pain20.02.02.001--Not Available
Blister23.03.01.001; 12.01.06.0020.000178%Not Available
The 1th Page    1 2 3 4 5    Next   Last    Total 10 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene